Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes: A Population-Based Study in Korea
| Autor: | Hyun Min Kim, Min Jin Kang, Sun Ok Song |
|---|---|
| Jazyk: | English<br />Korean |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Endocrinology and Metabolism, Vol 37, Iss 6, Pp 929-937 (2022) |
| Druh dokumentu: | article |
| ISSN: | 2093-596X 2093-5978 |
| DOI: | 10.3803/EnM.2022.1613 |
| Popis: | Background Cervical cancer is a prevalent malignancy that is a major health problem for women worldwide. The cancer-preventive properties of metformin are well-known, but insufficient data have been reported regarding its relationship to cervical cancer. Therefore, in a nationwide population-based study, we investigated the association between metformin use and cervical cancer incidence in patients with newly diagnosed type 2 diabetes. Methods This retrospective cohort study used the Korean National Health Insurance claims database. Individuals newly diagnosed with type 2 diabetes between January 2005 and December 2009 were included. The occurrence of cervical cancer was explored by matching for age, economic status, region of residence, and use of anti-diabetic medication. Results In total, 66,013 metformin users and 64,756 non-users were analyzed. Cervical cancer occurred in 219 metformin users (0.33%) and 274 metformin non-users (0.42%) (hazard ratio [HR], 0.783; 95% confidence interval [CI], 0.655 to 0.036; P=0.007). Moreover, cervical cancer risk was considerably reduced in those treated with a high dose (>1,200,000 mg) or for an extended period (≥2,000 days) compared to non-users (HR, 0.151; 95% CI, 0.093 to 0.243; P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|